IDI [IDI] DEF 14C: (Original Filing)
[]
IDI [IDI] SC 13D/A: (Original Filing)
[CUSIP No. 44938L108 2 10 Page 1. NAMES OF REPORTING PERSONS Phillip Frost, M.D. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) x ¨ (a) 3. SEC USE ONLY 4. SOURCE OF FUNDS (see instructions) N/A 5. ¨ 6. CITIZENSHIP OR PLACE OF ORGANIZATION]
IDI [IDI] SC 13D/A: CUSIP No. 44938L108 2 10 Page 1. NAMES
[CUSIP No. 44938L108 2 10 Page 1. NAMES OF REPORTING PERSONS Phillip Frost, M.D. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) x ¨ (a) 3. SEC USE ONLY 4. SOURCE OF FUNDS (see instructions) N/A 5. ¨ 6. CITIZENSHIP OR PLACE OF ORGANIZATION]
IDI [IDI] 8-K: IDI, Inc. Announces Business Update Information solutions provider
[IDI, Inc. Announces Business Update Information solutions provider expects strong growth during 2016; maintains solid cash position with positive cash flow; continued insider purchases despite current market conditions BOCA RATON, FL January 19, 2016 IDI, Inc. (NYSE MKT: IDI) -Strong current cash position; operating cash flow positive since the closing of the Fluent acquisition. -Recent insider purchases by] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): January 19, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 8.01 Other Events. Top of the Form]
IDI [IDI] 424B5: (Original Filing)
[Prospectus Supplement Page ABOUT THIS PROSPECTUS SUPPLEMENT S-ii S-iii PROSPECTUS SUMMARY S-1 THE OFFERING S-2 RISK FACTORS S-4 USE OF PROCEEDS S-18 DILUTION S-19 PRICE RANGE OF COMMON STOCK]
IDI [IDI] 424B5: Prospectus Supplement Page ABOUT THIS PROSPECTUS SUPPLEMENT S-ii
[Prospectus Supplement Page ABOUT THIS PROSPECTUS SUPPLEMENT S-ii S-iii PROSPECTUS SUMMARY S-1 THE OFFERING S-2 RISK FACTORS S-4 USE OF PROCEEDS S-18 DILUTION S-19 PRICE RANGE OF COMMON STOCK]
IDI [IDI] 8-K: (Original Filing)
[EXECUTION COPY IDI, INC. Common Stock ($0.0005 par value per share) Capital on Demand Sales Agreement JonesTrading Institutional Services LLC 780 Third Avenue New York, NY 10017 January 15, 2016 Ladies and Gentlemen: Company Agreement Agent IDI, INC. a Delaware corporation (the Issuance and Sale of Shares Placement Shares Common Stock Maximum Amount Commission 1. Securities Act ] [Akerman LLP One Southeast Third Avenue Suite 2500 Miami, FL 33131-1714 Tel: 305.374.5600 Fax: 305.374.5095 January 15, 2015 IDI, Inc. 2650 North Military Trail Suite 300 Boca Raton, FL 33431 Re: Registration Statement on Form S-3 Ladies and Gentlemen: akerman.com IDI, Inc. January 15, 2015 Page 2 We hereby consent to the filing of this opinion as part of the] [Risks Related to the Acquisition We have incurred significant additional indebtedness as a result of the Acquisition. We financed approximately $50.0 million of the cash portion of the purchase price of the Acquisition with the proceeds of the Securities Purchase Agreements and FGIT Stock Purchase Agreement, and the remaining $50.0 million with the proceeds from the Bridge Notes and Term] [Item 1.01. Entry into a Material Definitive Agreement. At-the Market Issuance Sales Agreement TM On January 15, 2016, IDI, Inc. (IDI) entered into an Capital on Demand IDI is not obligated to make any sales of Common Stock under the Sales Agreement and no assurance can be given that IDI will sell any shares under the Sales Agreement, or, if]
